Core Viewpoint - Exosomes have gained significant popularity in the medical beauty market, being referred to as a "darling of anti-aging" products, although their mechanisms and clinical testing remain largely unverified in the medical and academic fields [2][3]. Regulatory Environment - In June 2025, the National Medical Products Administration (NMPA) proposed to include exosomes with therapeutic functions under drug regulation, but no exosome products have received market approval in China as of now [5]. - Despite the lack of approval, unregulated exosome anti-aging products are prevalent in the medical beauty sector, often sold at high prices [5]. Market Practices - There are numerous instances of fraudulent practices in the exosome market, including false advertising and the promotion of products claiming to treat various diseases [7][11]. - Companies are marketing exosome products at different levels, with medical beauty being the lowest tier and claims of treating chronic diseases and even cancer at higher tiers [9][11]. Consumer Experiences - Reports from consumers indicate adverse effects from exosome treatments, including severe infections and allergic reactions, leading to significant dissatisfaction [16]. - Complaints highlight the lack of efficacy and the perception of being scammed, with many consumers expressing regret over their experiences with exosome treatments [16]. Company Profiles - Hunan Lishai Pharmaceutical Co., Ltd. has faced penalties for violating medical device regulations, indicating a problematic compliance history [19]. - Sichuan Jiebothiaer Biotechnology Co., Ltd. was established in May 2024, focusing on cell technology and health consulting, but has no reported employees as of 2024 [22]. - Sichuan Huamei Zixin Plastic Surgery Hospital Co., Ltd. has been fined for advertising violations, reflecting ongoing regulatory scrutiny in the medical beauty sector [23][24].